The role of chlamydia pneumoniae in cardiovascular disease

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 139-173

  Gaydos, Charlotte A ^a   Quinn, Thomas C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; HEAT SHOCK PROTEIN;

ANIMAL; ARTERIOSCLEROSIS; ARTERY; BLOOD; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CULTURE TECHNIQUE; DISEASE MODEL; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; REVIEW;

ANIMALS; ANTIBODIES, BACTERIAL; ARTERIES; ARTERIOSCLEROSIS; CELL ADHESION MOLECULES; CHEMOKINES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CULTURE TECHNIQUES; CYTOKINES; DISEASE MODELS, ANIMAL; HEAT-SHOCK PROTEINS; HUMANS;

EID: 0033629948     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (194)

1. McMillan G: Historical review of research on atherosclerosis. Adv Exp Med Biol 369:1-6, 1995.
2. Ross R: The pathogenesis of atherosclerosis - an update. N Eng J Med 314: 488-500. 1986.
3. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993.
4. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause, 1990-2020: Global burden of disease study. Lancet 349:1498-1504, 1997.
5. Wissler RW: An overview of the quantitative influence of several risk factors on progression of atherosclerosis plaques in human coronary arteries. Am J Med Sci 310:29S-36S, 1995.
6. Davies MJ: The composition of coronary-artery plaques. N Eng J Med 336:1312-1314, 1997.
7. Libby P: Atheroma: More than mush. Lancet 348: 4S-7S, 1996.
8. Alexander RW: Inflammation and coronary artery disease. N Eng J Med 331:468-469, 1994.
9. Wick G, Schett G, Amberger A, et al: Is atherosclerosis an immunologically mediated disease? Immunol Today 16:27-33, 1995.
10. Ross R: Atherosclerosis - An inflammatory disease. N Eng J Med 340:115-126, 1999.
11. Van der Wal AC, Becker AE, Van der Loos CM, et al: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89:34-44, 1994.
12. Liuzzo G, Biasucci L, Gallimore J, et al: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417-424, 1994.
13. Danesh J, Collins R, Appleby P, et al: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 279:1477-1482, 1998.
14. Ridker PM, Cushman M, Stampfer J, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. J Med 336:973-979, 1997.
15. Gupta S, Leatham EW: The relation between Chlamydia pneumoniae and atherosclerosis. Heart 77:7-8, 1997.
16. Sumpter MT, Dunn MI: Is coronary artery disease an infectious disease? Chest 112:302-303, 1997.
17. Vallance P, Collier J, Bhagat K: Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet 349:1391-1392, 1997.
18. Beck J, Garcia R, Heiss G, et al: Periodontal disease and cardiovascular disease. J Periodontol 67:11238-11375, 1996.
19. Gupta S, Leatham EW, Carrington D, et al: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404-407, 1997.
20. Gurfinkel E, Bozovich G, Daroca A, et al: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 350:404-407, 1997.
21. Rayer P: Memoire sur l'ossification morbide, consideree comme une termination des phlegmasies. Arch Gen Med J (Paris) 1:313-335, 1923.
22. Karsner HT, Bayless F: Coronary arteries in rheumatic fever. Am Heart J 9:557-585, 1934.
23. Thayer WS: On the late effects of typhoid fever on the heart and vessels. Am J Med Sci 77:391-422, 1904.
24. Frothingham C: The relation between acute infectious diseases and arterial lesions. Arch Intern Med 8:153-162, 1911.
25. Virchow R: Cellular Pathology as Based Upon Physiological and Pathological Histology [in German], ed 2, (English translation). Philadelphia, Pa, JB Lippincott, 1971.
26. Osler W: Diseases of the arteries, in Osler W, MacCrae T (eds): Modern Medicine: Its Theory and Practice in Original Contributions by American and Foreign Authors. Philadelphia, Pa, Lea and Febiger, 1908, pp 426-447.
27. Nieto JF: Infections and atherosclerosis: New clues from an old hypothesis? Am J Epidemiol 148:937-948, 1998.
28. Mattila KJ: Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med 225:293-296, 1989.
29. Spodick DH, Flessas AP, Johnson MM: Association of acute respiratory symptoms with onset of acute myocardial infarction: Prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 53:481-482, 1984.
30. Bainton D, Jones GR, Hole D: Influenza and ischaemic heart disease - a possible trigger for acute myocardial infarction? Int J Epidemiol 7:231-239, 1978.
31. Sohal RS, Burch GE, Chu KC, et al: Ultrastructural changes in cardiac capillaries of Coxsackie B4-infected mice. Lab Invest 19:399-405, 1968.
32. Speir E, Modali R, Huang ES, et al: Potential role of human ctyomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394, 1994.
33. Wu TC, Hruban RH, Ambinder RF, et al: Demonstration of cytomeglovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol 140:739-747, 1992.
34. Fernando S, Booth J, Boriskin Y, et al: Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using the polymerase chain reaction. J Med Virol 42:170-174, 1994.
35. Melnick JL, Hu CH, Burek J, et al: Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 42:396-404, 1994.
36. Mattila KJ, Valtonen W, Nieminen MS, et al: Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 26:719-734, 1998.
37. Jackson LA, Campbell LA, Kuo CC, et al: Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 176:292-295, 1997.
38. Saikku P, Leinonen M, Tenkanen L, et al: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 116:273-278, 1992.
39. Saikku P, Leinonen M, Mattila K, et al: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2:983-985, 1988.
40. Saikku P: Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J 14:62S-65S, 1993.
41. Shor A, Kuo CC, Patton DL: Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 82:158-161, 1992.
42. Campbell LA, O'Brien ER, Cappuccio AL, et al: Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 172:585-588, 1995.
43. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: Is there a link? Lancet 350:430-436, 1997.
44. Boman J, Soderberg S, Forsberg J, et al: High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 178:274-277, 1998.
45. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-1013, 1997.
46. Grayston JT, Kuo CC, Campbell LA, et al: Chlamydia pneumonias sp nov for Chlamydia sp. strain TWAR. Int J Syst Bacteriol 39:88-90, 1989.
47. Grayston JT, Campbell LA, Kuo CC, et al: A new respiratory tract pathogen: Chlamydia pneumoniae, strain TWAR. J Infect Dis 161:618-625, 1990.
48. Grayston JT, Kuo CC, Wang SP, et al: A new Chlamydia psittaci strain TWAR isolated in acute respiratory tract infections. N Engl J Med 315:161-168, 1986.
49. Campbell LA, Kuo CC, Grayston JT: Characterization of the new Chlamydia agent, TWAR, as a unique organism by restriction endonuclease analysis and DNA-DNA hybridization. J Clin Microbiol 25:1911-1916, 1987.
50. Campbell LA, Kuo CC, Grayston JT: Structural and antigenic analysis of Chlamydia pneumoniae. Infect Immun 58:93-97, 1990.
51. Kuo CC, Chen HH, Wang SP, et al: Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol 24:1034-1037, 1986.
52. Kuo CC, Chi EY, Grayston JT: Ultrastructure study of entry of Chlamydia strain TWAR into HeLa cells. Infect Immun 56:1668-1672, 1988.
53. Gaydos CA, Palmer L, Quinn TC, et al: Phylogenetic relationship of Chlamydia pneumoniae to Chlamydia psittaci and Chlamydia trachomatis as determined by analysis of 16S ribosomal DNA sequences. Int J Syst Bacterial 43:610-612, 1993.
54. Grayston JT: Chlamydia pneumoniae, strain TWAR. Chest 95:664-669, 1989.
55. Grayston JT: Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 15:757-763, 1992.
56. Chirgwin K, Roblin PM, Gelling M, et al: Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 163:757-761, 1991.
57. Marrie TJ, Grayston JT, Wang SP, et al: Pneumonia associated with the TWAR strain of Chlamydia. Ann Intern Med 106:507-511, 1987.
58. Grayston JT, Diwan VK, Cooney M, et al: Community and hospital acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 149:169-173, 1989.
59. Fang GD, Fine M, Orloff J, et al: New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 395 cases. Medicine 69:307-316, 1990.
60. Chomarat M, Cahen R, Durieu I, et al: Isolation of Chlamydia pneumoniae from the maxillary sinus of a patient with purulent sinusitis. Clin Infect Dis 15:570-571, 1992.
61. Grayston JT, Aldous MB, Easton A, et al: Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 168:1231-1235, 1993.
62. Gaydos CA, Eiden JJ, Oldach D, et al: Diagnosis of Chlamydia pneumoniae infection in paitents with community-acquired pneumonia by polymerase chain reaction enzyme immunoassy. Clin Infect Dis 19:157-160, 1994.
63. Hahn DL, Dodge RW, Golubjatnikou R: Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 266:225-230, 1991.
64. Emre U, Roblin PM, Gelling M, et al: The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 148:727-732, 1994.
65. Miller ST, Hammerschlag MR, Chirgwin K, et al: Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr 118:30-33, 1991.
66. Augenbraun MH, Roblin PM, Chirgwin K, et al: Isolation of Chlamydia pneumoniae from lungs of patients infected with the human immunodeficiency virus. J Clin Microbiol 29:401-402, 1991.
67. Haidl S, Ivarsson S, Bjerre I, et al: Guillain-Barré syndrome after Chlamydia pneumoniae infection. N Engl J Med 326:576-577, 1992.
68. Marrie TJ, Harczy M, Mann OE, et al: Culture-negative endocarditis probably due to Chlamydia pneumoniae. J Infect Dis 161:127-129, 1990.
69. Ogawa H, Fujisawa T, Kazuyama Y: Isolation of Chlamydia pneumoniae from middle ear aspirates of otitis media with effusion: A case report. J Infect Dis 162:1000-1001, 1990.
70. Gaydos CA, Fowler CL, Gill VJ, et al: Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in an immunocompromised population. Clin Infect Dis 17:718-723, 1993.
71. Hammerschlag MR, Chirgwin K, Roblin PM, et al: Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 14:178-182, 1992.
72. Hyman CL, Augenbraun MH, Roblin PM, et al: Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR. J Clin Microbiol 29:2082-2083, 1991.
73. Gnarpe J, Gnarpe H, Sundelof B: Endemic prevalence of Chlamydia pneumoniae in subjectively healthy persons. Scand J Infect Dis 23:387-388, 1991.
74. Hyman CL, Roblin PM, Gaydos CA, et al: Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: Assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis 20:1174-1178, 1995.
75. Saikku P, Mattila K, Nieminen MS, et al: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1:983-985, 1988.
76. Saikku P, Leinonen M, Tenkanen L, et al: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Int Med 116:273-278, 1992.
77. Thom DH, Wang S-P, Grayston JT, et al: Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 11:547-551, 1991.
78. Shor A, Kuo CC, Patton DL: Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 82:158-161, 1992.
79. Kuo C-C, Shor A, Campbell LA, et al: Demonstration of Chlamydia pneumonias in atherosclerotic lesions of coronary arteries. J Infect Dis 167:841-849, 1993.
80. Kleemola M, Saikku P, Visakorpi R, et al: Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis 157:230-236, 1988.
81. Saikku P, Wang SP, Kleemola M, et al: An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 151:832-839, 1985.
82. Pether JVS, Noah ND, Lau YK, et al: An outbreak of psittacosis in a boys' boarding school. J Hyg 92:337-343, 1984.
83. Pether JVS, Wang SP, Grayston JT: Chlamydia pneumoniae, strain TWAR, as the cause of an outbreak in a boys' school previously called psittacosis. Epidemiol Infect 103:395-400, 1989.
84. Wang SP, Kuo CC, Grayston JT: Formalinized Chlamydia trachomatis organisms as antigens in the micro-immunofluorescence test. J Clin Microbiol 10:259-261, 1979.
85. Wang SP, Grayston JT: Micro-immunofluorescence serology of Chlamydia trachomatis, in de la Maza LM (ed): Medical Virology III. The 1983 International Symposium on Medical Virology. New York, Elsevier Science, 1984, pp 87-118.
86. Mordhorst CH, Wang SP, Grayston JT: Epidemic "ornithosis" and TWAR infection, Denmark, 1976-1985, in Oriel D, Ridgeway G, Schachter J, et al (eds): Chlamydial Infections. Cambridge, Proceedings of the Sixth International Symposium on Human Chlamydial Infections, 1986.
87. Forsey T, Darougar S, Treharne JD: Prevalence in human beings of antibodies to Chlamydia 10L-207, an atypical strain of Chlamydia. J Infect 12:145-152, 1986.
88. Grayston JT, Wang SP, Kuo CC, et al: Current knowledge of Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases. Eur J Microbiol Infect Dis 89:191-202, 1998.
89. Grayston JT: Chlamydia pneumoniae, strain TWAR, in Bowie WR, Caldwell HD, Jones RD, et al (eds): Chlamydial Infections. Cambridge, Cambridge University, 1990, pp 389-401.
90. Grayston JT, Mordhorst C, Bruu A-L, et al: Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1981-1983. J Infect Dis 159:1111-1114, 1989.
91. Grayston JT, Kuo CC, Wang SP, et al: Clinical findings in TWAR respiratory tract infections, in Oriel J, Byrne GI, Chernesky MA (eds): Chlamydial Infections. Cambridge, Cambridge University, 1986, pp 337-340.
92. Verkooyen RP, Hazenberg MA, Van Haaren GH, et al: Age-related interference with Chlamydia pneumoniae microimmunofluoresence serology due to circulating rheumatoid factor. J Clin Microbiol 30:1287-1290, 1992.
93. Kern DG, Neill MA, Schachter J: A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Chest 104:208-213, 1993.
94. Gaydos CA, Roblin PM, Hammerschlag MR, et al: Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 32:903-905, 1994.
95. Kutlin A, Roblin PM, Hammerschlag MR: Antibody response to Chlamydia pneumoniae infection in children with respiratory illness. J Infect Dis 177:720-724, 1998.
96. Wimmer ML, Sandmann-Strupp R, Saikku P, et al: Association of chlamydial infection with cerebrovascular disease. Stroke 27:2207-2210, 1996.
97. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: Is there a link? Lancet 350:430-436, 1997.
98. Mantovani A, Bussolino F, Introna M: Cytokine regulation of endothelial cell function: From molecular level to the bedside. Immunol Today 18:231-240, 1997.
99. Carlsson J, Miketic S, Mueller K-H, et al: Previous cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty. Lancet 350:1225, 1998.
100. Wang SP, Grayston JT: Microimmunofluorescence serology in Chlamydia trachomatis, in de la Maza LM (ed): 2083 International Symposium on Medical Virology, New York, Elsevier Science, 1984, pp 87-118.
101. Leinonen M, Linnanmaki E, Mattila K, et al: Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog 9:67-73, 1990.
102. Linnanmaki E, Leinonen M, Mattila K, et al: Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 87:1130-1134, 1993.
103. Karvonen M, Tuomilehto J, Pitkaniemi J, et al: Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 23:1315-1321, 1994.
104. Hahn DL, Golubjatnikov R: Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 12:945-947, 1992.
105. Libby P, Egan D, Skarlotos S: Roles of infectious diseases in atherosclerosis and restenosis: An assessment of the evidence and need for future research. Circulation 96:4095-4103, 1997.
106. Davidson M, Kuo C-C, Middaugh JP, et al: Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 98:628-633, 1998.
107. Puolakkainen M, Kuo CC, Shor A, et al: Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 31:2212-2214, 1993.
108. Campbell LE, Kuo C-C, Grayston JT: Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis 4:571-579, 1998.
109. Kuo CC, Gown AM, Benditt EP, et al: Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 13:1501-1504, 1993.
110. Blasi F, Denti F, Erba M, et al: Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 34:2766-2769, 1996.
111. Juvonen J, Juvonen T, Laurila A, et al: Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 25:499-505, 1996.
112. Juvonen J, Juvonen T, Laurila A, et al: Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms. Ann N Y Acad Sci 800:236-238, 1996.
113. Maass M, Krause E, Engel PM: Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology 48:699-706, 1997.
114. Maass M, Krause E, Kruger S, et al: Coronary arteries harbour viable Chlamydia pneumoniae. J Clin Infect 3, suppl 2:136, 1997.
115. Chiu B, Viira E, Tucker W, et al: Chlamydia pneumoniae, cytomegalovirus and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 86:2144-2148, 1997.
116. Yamashita K, Ouchi K, Shirai M, et al: Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 29:773-778, 1998.
117. Ong G, Thomas BJ, Mansfield AO, et al: Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 49:102-106, 1996.
118. Kuo CC, Coulson AS, Campbell LA, et al: Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 26:29-31, 1997.
119. Blasi F, Cosentini R, Raccanelli R, et al: A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 112:309-312, 1997.
120. Juvonen J, Laurila A, Juvonen T, et al: Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 29:1054-1059, 1997.
121. Nystrom-Rosander C, Thelin S, Hjelm E, et al: High incidence of Chlamydia pneumoniae in sclerotic heart valve of patients undergoing aortic valve replacement. Scand J Infect Dis 29:361-365, 1997.
122. Juvonen JJT, Laurika A, Kuusisto J, et al: Can degenerative tricuspid aortic valve stenosis be caused by a persistent Chlamydia pneumoniae infection? Ann Intern Med 128:741-744, 1998.
123. Weiss S, Roblin P, Gaydos C, et al: Failure to detect Chlamydia pneumoniae (Cp) in coronary atheromas of patients undergoing atherectomy, in Orfila J, Byrne GI, Chernesky MA, et al (eds): Chlamydial Infections. Bologna, Italy, Societa Editrice Esculapio, 1994, pp 220-223.
124. Ramirez JA: The Chlamydia pneumoniae/Atherosclerosis Study Group: Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 125:979-982, 1996.
125. Gaydos CA, Quinn TC, Bobo LD, et al: Similarity of Chlamydia pneumoniae strains in the variable domain IV region of the major outer membrane protein gene. Infect Immun 60: 5319-5323, 1992.
126. Molestina RE, Dean D, Miller RD, et al: Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells. Infect Immun 66:1370-1376, 1998.
127. Maass M, Bartells C, Engel PM, et al: Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 31:827-832, 1998.
128. Gieffers J, Solbach W, Maass M: In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother 42:2762-2764, 1998.
129. Beatty WL, Byrne GI, Morrison RP: Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci U S A 90: 3998-4002. 1993.
130. Beatty WL, Morrison RP, Byrne GI: Persistent chlamydiae: From cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58: 686-699. 1994.
131. Tsumura N, Emre U, Roblin P, et al: Effect of Hydrocortisone succinate on growth of Chlamydia pneumoniae in vitro. J Clin Microbiol 34:2379-2381, 1996.
132. Tjhie JH, Roosendaal R, MacLaren DM, et al: Improvement of growth of Chlamydia pneumoniae on HEp-2 Cells by pretreatment with additional centrifugation and extension of culture time. J Clin Microbiol 35:1883-1884, 1997.
133. Kazuyama Y, Lee SM, Amamiya K, et al: A novel method for isolation of Chlamydia pneumoniae by treatment with trypsin or EDTA. J Clin Microbiol 35:1624-1626, 1997.
134. Jackson LA, Campbell LA, Schmidt RA, et al: Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am J Pathol 150:1785-1790, 1997.
135. Gupta S, Camm AJ: Chlamydia pneumoniae and coronary heart disease. BMJ 314:1778-1779, 1997.
136. Gaydos CA, Summersgill JT, Sahney NN, et al: Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 64:1614-1620, 1996.
137. Godzik KL, O'Brien ER, Wang SK, et al: In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 33:2411-2414, 1995.
138. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, et al: Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 16:313-319, 1994.
139. Knoebel E, Vijayagopal P, Figueroa JE 2d, et al: In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun 65:503-506, 1997.
140. Kalayoglu MV, Byrne GI: Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 177:725-729, 1998.
141. Kalayoglu MV, Byrne GI: A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 66:5067-5072, 1998.
142. Davies MJ, Richardson PD, Woolf N, et al: Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69: 377-381, 1993.
143. Libby P: Molecular bases of the acute coronary syndromes. Circulation 91:2844-2850, 1995.
144. Ellis RW: Infection and coronary heart disease. J Med Microbiol 46:535-539, 1997.
145. Kol A, Libby P: The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations. Trends Cardiovasc Med 8:191-199, 1998.
146. Molestina RE, Miller RD, Ramirez JA, et al: Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun 67:1323-1330, 1999.
147. Hunt B, Jurd K: Endothelial cell activation, a central pathophysiological process. BMJ 316:1328-1329, 1998.
148. Frenette P, Wagner D: Adhesion molecules:II. Blood vessels and blood cells. N Engl J Med 335:43-45, 1996.
149. Bhagat K, Collier J, Vallance P: Endothelial stunning following a brief exposure to endotoxin: A mechanism to link infection to infarction? Cardiovasc Res 32:822-829, 1996.
150. Vallance P, Collier J, Bhagat K: Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet 349:1391-1392, 1997.
151. Collins T, Read M, Neish A, et al: Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J 9:899-909, 1995.
152. Kelly KA, Walker JC, Jameel SH, et al: CD4 cells in the upper genital tract correlate with expression of VCAM-1 and functional adhesion following chlamydial infection. Stephens RS, Byrne GI, Christiansen G, et al (eds): Proceedings of the 9th International Symposium on Human Chlamydial Infection, 1998, pp 391-394.
153. Kelly K, Rank R: Identification of homing receptors that mediate the recruitment of CD4 cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 65:5198-5208, 1997.
154. Uyemura KV, Demer LL, Castle SC, et al: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97: 2130-2138. 1996.
155. Morrison RP, Belland RJ, Lyng K, et al: Chlamydial disease pathogenesis. The 57-kd chlamydial hypersensitivity antigen is a stress response protein. J Exp Med 170: 1271-1283, 1989.
156. Xu Q, Willeit J, Marosi M, et al: Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 341:255-259, 1993.
157. Peeling RW, Brunham RC: Chlamydiae as pathogens: New species and new issues. Emerg Infect Dis 2:307-319, 1996.
158. Eckert L, Hawes S, Wolner-Hanssen P, et al: Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. J Infect Dis 173:1437-1444, 1997.
159. Brunham RC, Peeling RW: Chlamydia trachomatis antigens: Role in immunity and pathogenesis. Infect Agents Dis 3:218-233, 1994.
160. Peeling R, Bailey R, Conway J, et al: Antibody response to the 60-kd chlamydial heatshock protein is associated with scarring trachoma. J Infect Dis 177:256-259, 1998.
161. Claman P, Honey L, Peeling R, et al: The presence of serum antibody to the chlamydial heat shock protein (CHSP60) as a diagnostic test for tubal factor infertility. Fertil Steril 67:501-504, 1997.
162. Beatty WL, Morrison RP, Byrne GI: Immunoelectron-microscopic quantitation of differential levels of chlamydial proteins in a cell culture model of persistent Chlamydia trachomatis infection. Infect Immun 62:4059-4062, 1994.
163. Gaydos C, Pham D, Quinn T: Growth suppression of Chlamydia pneumoniae by interferon-g in U-937 macrophages and HEp-2 cells. Presented at the Annual Meeting of the American Society of Microbiology D-171:278, 1995.
164. Summersgill JT, Sahney NN, Gaydos CA, et al: Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. Infect Immun 63:2801-2803, 1995.
165. Mehta SJ, Miller RD, Ramirez JA, et al: Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: Role of tryptophan catabolism. J Infect Dis 177:1326-1331, 1998.
166. Yi Y, Zhong G, Brunham RC: Continuous B-cell epitopes in Chlamydia trachomatis heat shock protein 60. Infect Immun 1993;61:1117-1120.
167. Domeika M, Domeika K, Paavonen J, et al: Humoral immune responses to conserved epitopes of the Chlamydia trachomatis and human 60-kd heat-shock proteins in women with pelvic inflammatory disease. J Infect Dis 177:714-719, 1998.
168. Witkin S, Jeremias J, Toth M, et al: Proliferative response to conserved epitopes of the Chlamydia trachomatis and human 60-kilodalton heat-shock proteins by lymphocytes from women with salpingitis. Am J Obstet Gynecol 171:455-460, 1994.
169. Kol A, Sukhova G, Lichtman A, et al: Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-a and matrix metalloproteinase expression. Circulation 98:300-307, 1998.
170. Kleindiest R, Xu Q, Willeit J, et al: Immunology of atherosclerosis: Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 142:1927-1937, 1993.
171. Schett G, Xu Q, Amberger A, et al: Autoantibodies against heat shock protein 60 mediate endothelial cytotoxity. J Clin Invest 96:2569-2577, 1995.
172. Airenne S, Surcel H-M, Alakarppa H, et al: Chlamydia pneumoniae infection in human monocytes. Infect Immun 67:1445-1449, 1999.
173. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, et al: Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog 21:407-411, 1996.
174. Fryer RH, Schwobe EP, Woods ML, et al: Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 45:168-174, 1997.
175. Halme S, Syrjala H, Bloigu A, et al: Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease. Eur Heart J 18:1095-1101, 1997.
176. Halme S, Surcel HM: Cell mediated immunity to Chlamydia pneumoniae. Scand J Infect Dis Suppl 104:18-21, 1997.
177. Moazed TC, Kuo C, Patton DL, et al: Experimental rabbit models of Chlamydia pneumoniae infection. Am J Pathol 148:667-676, 1996.
178. Yang ZP, Kuo CC, Grayston JT: A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect Immun 61: 2037-2040, 1993.
179. Laitinen K, Alakarppa H, Laurila A, et al: Animal models for Chlamydia pneumoniae infection. Scand J Infect Dis Suppl 104:15-17, 1997.
180. Holland SM, Taylor HR, Gaydos CA, et al: Experimental infection with Chlamydia pneumoniae in nonhuman primates. Infect Immun 58:593-597, 1990.
181. Fong IW, Chiu B, Viira E, et al: Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 35:48-52, 1997.
182. Muhlestein JB, Anderson JL, Hammond EH, et al: Infection with C. pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97:633-636, 1998.
183. Moazed TC, Kuo C, Grayston JT, et al: Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 175:883-890, 1997.
184. Moazed TC, Kuo C, Grayston JT, et al: Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 177: 1322-1325, 1998.
185. Moazed TC, Campbell LA, Rosenfield ME, etal: Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein (APO-E) deficient mice. Stephens RS, Byrne GI, Christiansen G (eds): 9th International Symposium of Human Chlamydial Infection, 1998, pp 426-429. San Francisco, International Chlamydial Symposium.
186. Bachmaier K, Neu N, de la Maza LM, et al: Chlamydia infections and heart disease linked through antigenic mimicry. Science 283:1335-1339, 1999.
187. Lip GY, Beevers DG: Can we treat coronary artery disease with antibiotics? Lancet 350:378-379, 1997.
188. Martin D, Bursill J, Qui MR, et al: Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 351:1858-1859, 1998.
189. Meier CR, Derby LE, Jick SS, et al: Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281:427-431, 1999.
190. Welsh LE, Gaydos CA, Quinn TC: In vitro evaluation of activities of azithromycin, erythromycin and tetracycline against Chlamydia trachomatis and Chlamydia pneumonias. Antimicrob Agents Chemother 36:291-294, 1992.
191. Hammerschlag MR, Qumei KK, Roblin PM: In vitro activities of azithromycin, clarithromyciin, L-ofloxin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 36:1573-1574, 1992.
192. Hammerschlag MR: Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother 38:1873-1878, 1994.
193. Welch L, Gaydos C, Quinn TC: In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 40:212-214, 1996.
194. Folsom AR: Antibiotics for prevention of myocardial infarction? Not yet! JAMA 281:461-462, 1999.